NO20062420L - Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer - Google Patents

Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer

Info

Publication number
NO20062420L
NO20062420L NO20062420A NO20062420A NO20062420L NO 20062420 L NO20062420 L NO 20062420L NO 20062420 A NO20062420 A NO 20062420A NO 20062420 A NO20062420 A NO 20062420A NO 20062420 L NO20062420 L NO 20062420L
Authority
NO
Norway
Prior art keywords
treatment
chemotherapeutic agent
oligomer
iap
proliferative diseases
Prior art date
Application number
NO20062420A
Other languages
English (en)
Inventor
Eric Lacasse
Daniel Mcmanus
Jon P Durkin
Original Assignee
Aegera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegera Therapeutics Inc filed Critical Aegera Therapeutics Inc
Publication of NO20062420L publication Critical patent/NO20062420L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfinnelsen angår anvendelsen av en antisenseoligomer til XIAP, HIAP-1 eller HIAP-2 og et kjemoterapeutisk middel og sammensetninger og sett derav, for behandling av proliferative sykdommer.
NO20062420A 2003-10-30 2006-05-29 Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer NO20062420L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51626303P 2003-10-30 2003-10-30
PCT/CA2004/001900 WO2005042030A1 (en) 2003-10-30 2004-10-29 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
NO20062420L true NO20062420L (no) 2006-07-31

Family

ID=34549513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062420A NO20062420L (no) 2003-10-30 2006-05-29 Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer

Country Status (17)

Country Link
US (1) US8012944B2 (no)
EP (1) EP1691842A4 (no)
JP (1) JP2007509861A (no)
KR (1) KR20060127393A (no)
CN (2) CN1901939A (no)
AU (1) AU2004284855A1 (no)
BR (1) BRPI0415779A (no)
CA (1) CA2542884A1 (no)
IL (1) IL175242A0 (no)
MX (1) MXPA06004920A (no)
NO (1) NO20062420L (no)
NZ (1) NZ547191A (no)
RU (2) RU2376018C2 (no)
SG (1) SG157422A1 (no)
TW (1) TWI332841B (no)
WO (1) WO2005042030A1 (no)
ZA (1) ZA200603399B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US7601497B2 (en) * 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
IL164228A0 (en) 2002-03-27 2005-12-18 Aegera Therapeutics Inc Antisense iap nucleobase oligomers and uses thereof
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US20080293653A1 (en) * 2004-10-14 2008-11-27 Jon Durkin Method of treating autoimmune diseases
EP2368988A1 (en) * 2005-09-19 2011-09-28 Isis Pharmaceuticals, Inc. Modulation of Glucocorticoid Receptor Expression
WO2007125173A2 (en) * 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
US7618992B2 (en) * 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
EP2197457A4 (en) * 2007-09-26 2010-10-27 Aparna Biosciences THERAPEUTIC VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS
US8288520B2 (en) * 2008-10-27 2012-10-16 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and system
CA2750338C (en) * 2009-01-28 2019-06-25 Qiagen Gaithersburg, Inc. Sequence-specific large volume sample preparation method and assay
EP2425019B1 (en) * 2009-05-01 2014-03-19 QIAGEN Gaithersburg, Inc. A non-target amplification method for detection of rna splice-forms in a sample
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2529031B1 (en) 2010-01-29 2014-07-09 QIAGEN Gaithersburg, Inc. Method of determining and confirming the presence of hpv in a sample
JP6103941B2 (ja) * 2010-01-29 2017-03-29 キアジェン ゲイサーズバーグ インコーポレイテッド 核酸の配列特異的精製および多重分析のための方法および組成物
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
EP2572001A2 (en) 2010-05-19 2013-03-27 QIAGEN Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
AU2011299233B2 (en) 2010-09-07 2016-09-15 Integrated Dna Technologies, Inc. Modifications for antisense compounds
CN103597095B (zh) 2011-02-24 2016-08-17 奇亚根盖瑟斯堡股份有限公司 用于检测hpv核酸的材料和方法
CN102731591B (zh) * 2011-03-30 2016-12-14 江苏中康药物科技有限公司 一种抗肿瘤、抗病毒的化合物、其制备方法及用途
MX350944B (es) 2011-10-25 2017-09-26 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de gccr.
CN105264091B (zh) * 2013-03-14 2020-02-28 Ionis制药公司 用于调节tau表达的组合物和方法
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2017214553A1 (en) * 2016-06-09 2017-12-14 The General Hospital Corporation Modulating the cellular stress response
RU2664182C2 (ru) * 2016-12-05 2018-08-15 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Способ получения препарата для регуляции численности комара обыкновенного (Culex pipiens)
CN108794569A (zh) * 2018-06-27 2018-11-13 南开大学 天然产物Symplostatin4衍生物及其在制备抗癌症干细胞药物中的应用
TW202133842A (zh) * 2019-12-02 2021-09-16 大陸商蘇州亞盛藥業有限公司 Iap抑制劑與parp或mek抑制劑或其他化學治療劑的組合
EP4093409A4 (en) * 2020-01-23 2024-01-10 Univ Southern California ANTAGONISM AS THERAPY FOR TDP-43 PROTEINOPATHIES
CN110982876B (zh) * 2020-03-04 2020-05-26 圣湘生物科技股份有限公司 病毒核酸检测的预处理方法、预处理液、试剂盒及其用途
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5594076A (en) * 1991-09-24 1997-01-14 The Pennsylvania Research Foundation Hydrodegradable polyesters
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
WO1996035703A1 (en) 1995-05-11 1996-11-14 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
US20030073159A1 (en) * 1992-05-11 2003-04-17 Human Genome Sciences, Inc. Human inhibitor of apoptosis gene 1
WO1994006814A1 (en) 1992-09-14 1994-03-31 The General Hospital Corporation Ikaros: a t cell pathway regulatory gene
US5958771A (en) * 1998-12-03 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of cellular inhibitor of Apoptosis-2 expression
US5958772A (en) * 1998-12-03 1999-09-28 Isis Pharmaceuticals Inc. Antisense inhibition of cellular inhibitor of apoptosis-1 expression
US6087173A (en) 1999-09-09 2000-07-11 Isis Pharmaceuticals Inc. Antisense modulation of X-linked inhibitor of apoptosis expression
US5718883A (en) * 1993-04-14 1998-02-17 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
AU2290195A (en) 1994-04-13 1995-11-10 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
PL317197A1 (en) 1994-05-10 1997-03-17 Immulogic Pharma Corp Compositions for and method of treating sclerosis multiplex
US6020127A (en) * 1994-10-18 2000-02-01 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
CZ122697A3 (en) 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
WO1996020950A2 (en) 1995-01-06 1996-07-11 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
US5770690A (en) * 1995-06-27 1998-06-23 Neurex Corporation Bax omega protein and methods
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5919912A (en) * 1995-08-04 1999-07-06 University Of Ottawa Mammalian IAP antibodies and diagnostic kits
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
AU6692996A (en) 1995-08-08 1997-03-05 Tularik Inc. Inhibitors of apoptosis
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
AUPN727595A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic compositions
US5605022A (en) * 1995-12-26 1997-02-25 Nci Building Systems, Inc. Vented closure
GB9601108D0 (en) 1996-01-19 1996-03-20 Univ Ottawa Neuronal apoptosis inhibitor protein (NAIP)
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
WO1998022131A2 (en) 1996-11-15 1998-05-28 University Of Ottawa Modulators of ovarial apoptosis related to iap
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
CA2225187A1 (en) * 1997-07-14 1999-01-14 Universite D'ottawa/ University Of Ottawa Xaf genes and polypeptides: methods and reagents for modulating apoptosis
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6417160B1 (en) * 1997-10-14 2002-07-09 Nadine A. Tatton Methods for increasing schwann cell survival
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6171821B1 (en) 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
EP1117391A2 (en) * 1998-10-09 2001-07-25 L. Sai Latha Shankar Methods for treating multiple sclerosis
KR20000065690A (ko) 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
KR100397275B1 (ko) * 2001-03-08 2003-09-17 주식회사 웰진 단방향성 안티센스 ｃＤＮＡ 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템
AU2003228301A1 (en) 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
IL164228A0 (en) * 2002-03-27 2005-12-18 Aegera Therapeutics Inc Antisense iap nucleobase oligomers and uses thereof
EP1469070A1 (en) 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livin-specific siRNAs for the treatment of therapy-resistant tumors
JP2007506440A (ja) * 2003-09-29 2007-03-22 トピジェン・ファルマスーティック・インコーポレーテッド 炎症性症状を含む疾患を治療するための、オリゴヌクレオチド組成物および方法
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent

Also Published As

Publication number Publication date
CN101862459A (zh) 2010-10-20
CN1901939A (zh) 2007-01-24
EP1691842A1 (en) 2006-08-23
RU2010101234A (ru) 2011-07-20
US20050119217A1 (en) 2005-06-02
KR20060127393A (ko) 2006-12-12
MXPA06004920A (es) 2007-02-16
IL175242A0 (en) 2006-09-05
US8012944B2 (en) 2011-09-06
CA2542884A1 (en) 2005-05-12
TW200528117A (en) 2005-09-01
EP1691842A4 (en) 2008-06-11
RU2376018C2 (ru) 2009-12-20
SG157422A1 (en) 2009-12-29
RU2006117024A (ru) 2007-12-10
BRPI0415779A (pt) 2006-12-26
TWI332841B (en) 2010-11-11
WO2005042030A1 (en) 2005-05-12
NZ547191A (en) 2009-08-28
ZA200603399B (en) 2007-09-26
AU2004284855A1 (en) 2005-05-12
JP2007509861A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
RS20060320A (en) Substituted indazole-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
UA86042C2 (en) Substituted indazole-o-glucosides
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
SE0301700D0 (sv) Novel compounds
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.
NO20080037L (no) Kombinasjon av pyrimidylaminobenzamidforbindelser og imatinib for behandling eller forbyggelse av proliferative sykdommer
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO20060420L (no) 2-aminobenzoylderivater
SE0300457D0 (sv) Novel compounds
ITSV20030016A1 (it) Sostanze contenenti tannini o miscele di tannini.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application